蛋白尿是影响全球几百万人的主要卫生保健问题,它是肾脏疾病的主要指标和预后标记物,也是心血管疾病患病率和死亡率的独立风险因素。微量白蛋白尿是糖尿病、肥胖和代谢综合征肾脏并发症的最早期指标。在慢性肾脏病的疾病发展过程中10%～50%的患者可出现显性蛋白尿,最终进展至透析或移植。因此,减少或阻止蛋白尿的发生是非常有意义的。 Proteinuria, the leading health-care problem affecting millions of people worldwide, is a leading marker and prognostic marker of kidney disease and is an independent risk factor for cardiovascular morbidity and mortality. Microalbuminuria is the earliest index of kidney complications of diabetes, obesity and metabolic syndrome. In the development of chronic kidney disease in 10% to 50% of patients with overt proteinuria may occur, the final progression to dialysis or transplantation. Therefore, reducing or preventing the occurrence of proteinuria is very significant.